key: cord-1050191-3su2d7pt
authors: Vandervore, Laura; Van Mieghem, Eugénie; Nowé, Vicky; Schouwers, Sofie; Steger, Charlotte; Abrams, Pascale; Schaeren, Jozef Van; Meskal, Anissa; Vandamme, Timon
title: False positive Herpes Simplex IgM serology in COVID-19 patients correlates with SARS-CoV-2 IgM/IgG seropositivity
date: 2022-01-31
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2022.115653
sha: f837c626c55b32c42d953d0b1c27dc34309d57a9
doc_id: 1050191
cord_uid: 3su2d7pt

Differentiating COVID-19 from other causes of viral pneumonia, like herpes simplex (HSV), can be complicated by shared clinical and laboratory features. Viral pneumonia is mostly diagnosed based on molecular or serological techniques. Serological immunoassay interferences, often attributed to concurrent appearance of heterologous (viral) immunoglobulins, is well-known, but has not been studied in COVID-19 patients. Following false positive HSV IgM results in our index patient, twenty-five other SARS-CoV-2 patients were tested for HSV-1/2 IgM with the chemiluminescent Liaison® assay and Euroimmun® ELISA. 45 % of COVID-19 patients tested positive for HSV IgM with Liaison®. No HSV indices were positive with Euroimmun® ELISA, suggesting immunoassay interference. Significant correlation between HSV IgM and SARS-CoV-2 IgM/IgG positivity was found. Adding 0.5% polyvinylpyrrolidone (PVP), inhibiting non-specific solid-phase adsorption, abolished interference in 22% of false positive cases, suggesting interference caused by solid-phase reactive IgM. Hence, serologic immunoassay results should be interpreted with caution in COVID-19 patients.

Immunoassays are commonly used as routine serological laboratory tests to demonstrate the presence of virus-specific immunoglobulins (IgM/IgG) in order to diagnose viral infections and determine course of treatment [1] . However, immunoassays may be subjected to interferences, causing false positive or false negative results. These erroneous serological results can have a major impact on clinical investigation, patient care and public health.

Hence, correct identification of known and novel interfering factors in serological assay is important. Frequently reported causes of positive interference are rheumatoid factor (RF) or other autoantibodies, heterophilic antibodies, human anti-animal antibodies (HAAA), albumin, complement, lysozyme, fibrinogen and paraproteins [2, 3] . Either these molecules cross-react by structurally resembling the analyte of interest, either through interaction with the antigen or antibody constituents of the assay, e.g. RF IgM binds the Fc fragment of human IgG's [4] .

In case of serological IgM detection on antigen-coated magnetic microparticles with chemiluminescent immunoassays (CLIA) of the Liaison® XL diagnostics platform (DiaSorin, Italy), interferences have been described due to the concurrent appearance of other immunoglobulins [1, [5] [6] [7] . During an outbreak of parvovirus B19 in 2009 it was shown that B19 IgM-positive sera had falsely elevated Epstein-Barr (EBV) IgM in 84% (57 out of 68) of cases and herpes simplex (HSV) IgM in 90% (61 out of 68) of cases [6] . Here, interference was attributed to the direct binding of IgM antibodies to the surface-modified polystyrene micro particles of other assays and were thus termed as 'solid-phase reactive antibodies' [5] .

Currently, humanity is facing the ongoing outbreak and rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the global COVID-19 pandemic. As of the beginning of December 2021, more than 264 million cases have been reported in 191 different countries [8] . In analogy to the falsely elevated results in B19 parvovirus IgM-positive sera, serology assays might also be affected in SARS-CoV-2 infected patients, particularly the HSV or EBV IgM CLIA [5, 6] .

Interpretation of potentially false positive HSV IgM serology results in COVID-19 patients can be complicated, since COVID-19 and HSV may present with similar clinical manifestations and laboratory results. Especially in immunocompromised hosts, disseminated HSV infections have been reported, presenting with meningitis, encephalitis, hepatitis and/or pneumonia. Cases of viral pneumonia due to HSV have also been described in immunocompetent hosts [9] . Differential diagnosis is further complicated by similar findings in HSV and SARS-CoV-2 associated pneumonia on high resolution Computed Tomography (HRCT) consisting of diffuse ground-glass attenuation and/or consolidations [10, 11] .

Moreover, confirmation of true positive HSV serology and HSV-associated pneumonia with other diagnostic tools is complicated since debate continues as to whether HSV nucleic acid detection in lower respiratory tract specimens, e.g. bronchoalveolar lavage fluid (BALF), with RT-PCR represents true clinical infection rather than innocuous viral shedding [12] . Besides sensitivity issues, collection of the necessary BALF specimen with bronchoscopy is relatively contra-indicated in patients with suspected COVID-19 and should only be considered in certain diagnostic or therapeutic settings [13] [14] [15] .

Up till now, non-specific binding to the solid phase of infectious-disease immunoassays remains elusive in COVID-19 patients. We hereby demonstrate false positive herpes simplex IgM serology in COVID-19 patients, and consistently link this interference to SARS-CoV-2

IgM/IgG seropositive samples. Furthermore, this paper shows the importance of interference elimination studies, providing clinical laboratories with answers to this interference during the ongoing COVID-19 crisis and potential new outbreaks in the future.

A cohort of COVID-19 affected individuals (N=26, 12 females, 14 males), requiring hospitalization at the GZA hospital group between March and May 2020, were included in this study ( Table 1) borderline ratio 0.8-1.0; negative ratio <0.8 and HSV-1/2 IgG positive cutoff ≥22 RU/mL; borderline cutoff 16-21 RU/mL; negative cutoff <16 RU/mL. Furthermore, the reference standard method (Real-time PCR) for HSV diagnostics was performed on the available BALFsamples by an external laboratory.

The presence of solid phase reactive antibodies was tested, by modifying the Liaison® HSV-1/2 IgM kit. Here, 0.1% and 0.5% polyvinylpyrrolidone (Sigma®, Saint Louis, USA, PVP-360) was added to the HSV-1/2 IgM dilution buffer (buffer A) as previously described [5] [6] [7] . This blocking agent is known to inhibit non-specific IgM reactivity through sterically hindering non-specific binding sites on the solid phase (i.e. magnetic particles). The HSV IgM results after both treatments were compared with original indices and statistically analyzed.

Standard quality control was performed after each assay modification.

Statistical analyses were performed using IBM SPSS statistics v. 26 (IBM Analytics) and Prism 5.0 (GraphPad Software). Linear regression analysis with logarithmic transformation was performed with MedCalc software. P-values of <0.05 were considered statistically significant. Significant differences between patients with and without SARS-CoV-2 virus specific antibodies were continuously compared with the Student's t test (in case of Gaussian distribution) and the Mann-Whitney U test (in case normality could not be assumed). Categorical variables were compared using the Fisher exact test. Results were presented as mean ± standard deviation or median (interquartile range), where appropriate. 8 A 44 year-old healthcare worker presented to the emergency department with fever, dry cough, thoracic pain and exertional dyspnea after working during several weeks in a nursing home with confirmed COVID-19 cases. SARS-CoV-2 RT-PCR test on nasopharyngeal swab at admission was negative. CT scan of the thorax showed diffuse peripheral alveolar consolidations, compatible with a viral pneumonia (Figure 1 ). Due to a high clinical and radiographic suspicion of COVID-19, the patient was placed in isolation. SARS-CoV-2 PCR was As SARS-CoV-2 PCR was repeatedly negative, an acute invasive HSV infection with viral pneumonia and viral hepatitis was withheld as a probable diagnosis. Bronchoscopy with BALF collection was performed for HSV 1/2 and SARS-CoV-2 PCR testing three days after admission. Intravenous (IV) therapy with acyclovir was initiated. However, 12 hours after the first dose our patient developed acute kidney injury due to intratubular precipitation of crystals, a known complication of IV administration of acyclovir [16] . After cessation of IV acyclovir and start of IV fluid therapy, kidney function normalized. Following recovery of his respiratory complaints, the patient was discharged from the hospital after 12 days. The HSV IgM levels fell over time, following resolution of his respiratory complaints. Results of PCR on BALF came back positive for SARS-CoV-2 (CT-value=26.23) and negative for HSV-1/2, which confirmed the COVID-19 diagnosis and raised the possibility of a false positive HSV serology in our patient. SARS-CoV-2 serology was also performed to confirm former SARS-CoV-2 infection in our patient and was positive for SARS-CoV-2 IgM and IgG. Hence, the cohort was expanded with 25 additional hospitalized RT-PCR confirmed COVID-19 patients with clinical characteristics, routine biochemical lab analysis, and HSV and SARS-CoV-2 serology summarized in Table 1 and Supplementary Table 1 After confirmation of the HSV IgM immunoassay interference, further analysis of our cohort was performed to determine causality. No significant correlation was found between RF positivity (n=2) and HSV IgM positivity within our total cohort (P=0.231). Presence of IgM's against other heterologous viruses (cytomegalovirus (CMV), EBV, human immunodeficiency virus (HIV), Hepatitis A/B/C/E) and Toxoplasma was ruled out when routine serology testing was available.

In our cohort, 57% of all PCR confirmed COVID-19 patients were found to be SARS-CoV-2 IgM positive and 85% (qualitative assay) to 92% (quantitative assay) IgG positive ( Table 1 and   Supplementary Table 1 

Since the presence of SARS-CoV-2 IgM and IgG seemed to correlate with false positive HSV IgM serology, interference elimination studies were performed on the available HSV reagent lot 327003 as previously described for the Liaison platform [5] [6] [7] . To test whether non- cases is bilateral pneumonia, with risk of progression to acute respiratory distress syndrome (ARDS) [17] . The most common finding on CT thorax are bilateral ground glass opacities with or without consolidation, with a predominant peripheral distribution. However, these findings are also common in other respiratory viral illnesses, such as adenovirus, varicella zoster virus (VZV), Epstein-Barr virus (EBV), respiratory syncytial virus (RSV) and cytomegalovirus [18] . HSV can also cause respiratory disease such as viral pneumonia, mainly in immunocompromised hosts, although immunocompetent hosts can be affected as well [9] . The differential diagnosis between different kinds of viral pneumonia can be complicated by false negative and false positive test results. Especially viral serological tests, which are frequently used in the diagnostic work-up for viral illnesses, are known to cause false positive or negative results, with occasionally serious clinical repercussions as a result.

Interference in serologic immunoassays can be caused by heterologous viral or non-specific immunoglobulins. This has not been sufficiently studied in COVID-19 cases, though SARS-CoV-2 infection has been reported to produce false positive reactions in a dengue serologic immunoassay [19] . Adding 0.5% PVP to the HSV IgM kit inhibited interference in 22% of all HSV IgM positive COVID-19 sera, but it would be interesting to see whether complete elimination is possible with increased PVP concentrations or a combination with 0.5% PVP and 0.005% PVA (polyvinyl alcohol), as earlier described [7] . Unfortunately, interference elimination studies could only be performed on the more recent HSV reagent lot 327003, whereas interference frequency was much higher with lot 327002, suggesting that PVP treatment would have been even more beneficial when using this kit. 

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Woloshin, S., N. 

Immunoglobulin M for Acute Infection: True or False? Clinical and vaccine immunology : CVI

Interferences in immunoassay

Interferences in Immunoassays

Interference by Rheumatoid Factor in Immunoglobulin M-Class Herpes Simplex Virus Types 1 + 2 Immunoassays

Prevention of assay interference in infectious-disease serology tests done on the liaison platform. Clinical and vaccine immunology : CVI

Acute parvovirus B19 infection frequently causes falsepositive results in Epstein-Barr virus-and herpes simplex virus-specific immunoglobulin M determinations done on the Liaison platform

Performance of the Epstein-Barr virus and herpes simplex virus immunoglobulin m assays on the liaison platform with sera from patients displaying acute parvovirus B19 infection

COVID-19 Dashboard by the

Herpes Simplex Pneumonia in an Immunocompetent Patient With Progression to Organizing Pneumonia

Herpes simplex virus pneumonia: high-resolution CT findings. The British journal of radiology

COVID-19): A Perspective from China

Herpes Simplex Virus-1 qPCR in the Diagnosis of Lower Respiratory Tract Infections in Organ Transplant Recipients and Critically Ill Patients

Does bronchoscopy help the diagnosis in Covid-19 infection?

Performing Bronchoscopy in Times of the COVID-19 Pandemic: Practice Statement from an International Expert Panel. Respiration

Society for Advanced Bronchoscopy Consensus Statement and Guidelines for bronchoscopy and airway management amid the COVID-19 pandemic

Acyclovir nephrotoxicity: a case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy. Case reports in medicine

Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Radiographic and CT Features of Viral Pneumonia

Covert COVID-19 and false-positive dengue serology in Singapore. The Lancet Infectious Diseases

HSV2 IgG (F.). In all cases SARS-CoV-2 IgM was determined with the COVID-19

Cypress Diagnostics®) and HSV IgM index was plotted in function of SARS-CoV-2 serology. P-values were calculated with the two-tailed Mann-Whitney U test

We would like to thank the clinical laboratory of AZ Sint-Maarten for providing the HSV IgM results on the Euroimmun® platform and the lab technicians of the GZA Sint-Augustinus hospital for helping with experiments. In addition, we would like to thank Sarah Vandamme, Geert Vandevyver, Laetitia Van den Bossche, Charlotte Cottignie, Michiel Lembrechts and Valent Intan-Goey for gathering and analyzing the clinical data.